Early data out of Israel suggests that a fourth dose of either the Pfizer/BioNTech or Moderna coronavirus vaccine can bring an increase in antibodies — more than what’s been seen after a third dose — but it still might not be enough to protect against breakthrough infections caused by the Omicron variant.
“These are very preliminary results. This is before any publication, but we’re giving it out since we understand the urgency of the public to get any information possible about the fourth dose,” Dr. Gili Regev-Yochay, director of the Infection Prevention and Control Unit at Sheba Medical Center, told reporters during a virtual news conference Monday about the data.
“We have a follow-up of the Pfizer vaccine for two weeks now, and we have a follow-up of the Moderna vaccine just for one week at this time point. And what we see is that the Pfizer vaccine, after two weeks, you see an enhancement or increase in the number of antibodies and neutralizing antibodies — a pretty nice increase. It’s even a little bit higher than what we had after the third dose,” Regev-Yochay said. “Yet, this is probably not enough for the Omicron.”
Read more at CNN.